Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jul;41(7):1594–1597. doi: 10.1128/aac.41.7.1594

In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

A B Brueggemann 1, K C Kugler 1, G V Doern 1
PMCID: PMC163966  PMID: 9210692

Abstract

The in vitro activity of a novel 8-methoxyquinolone, BAY 12-8039, against recent clinical isolates of Streptococcus pneumoniae (n = 404), Haemophilus influenzae (n = 330), and Moraxella catarrhalis (n = 250) was evaluated. Activity was compared to those of six other fluoroquinolones: ciprofloxacin, clinafloxacin, levofloxacin, ofloxacin, sparfloxacin and trovafloxacin. BAY 12-8039 and clinafloxacin had the highest levels of activity against S. pneumoniae, both with a MIC at which 90% of the isolates were inhibited (MIC90) of 0.06 microg/ml. Trovafloxacin and sparfloxacin were the next most active agents versus S. pneumoniae (MIC90s = 0.12 microg/ml). No differences in activity against penicillin-susceptible, -intermediate, or -resistant strains of S. pneumoniae were noted for any of the fluoroquinolones tested. MIC90s for the seven fluoroquinolones ranged from 0.008 to 0.06 microg/ml versus H. influenzae and from 0.008 to 0.12 microg/ml for M. catarrhalis. The MICs for two strains of S. pneumoniae and one strain of H. influenzae were noted to be higher than those for the general population of organisms for all of the fluoroquinolones tested. Finally, the activity of BAY 12-8039 versus S. pneumoniae was found to be diminished when MIC determinations were performed with incubation of agar dilution plates or broth microdilution trays in 5 to 7% CO2 versus ambient air.

Full Text

The Full Text of this article is available as a PDF (132.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andriole V. T. The future of the quinolones. Drugs. 1993;45 (Suppl 3):1–7. doi: 10.2165/00003495-199300453-00003. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Fuchs P. C., Brown S. D. In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents. Antimicrob Agents Chemother. 1996 Oct;40(10):2431–2433. doi: 10.1128/aac.40.10.2431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chin N. X., Gu J. W., Yu K. W., Zhang Y. X., Neu H. C. In vitro activity of sparfloxacin. Antimicrob Agents Chemother. 1991 Mar;35(3):567–571. doi: 10.1128/aac.35.3.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cruciani M., Bassetti D. The fluoroquinolones as treatment for infections caused by gram-positive bacteria. J Antimicrob Chemother. 1994 Mar;33(3):403–417. doi: 10.1093/jac/33.3.403. [DOI] [PubMed] [Google Scholar]
  5. Doern G. V., Brueggemann A. B., Pierce G., Hogan T., Holley H. P., Jr, Rauch A. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996 Dec;40(12):2884–2886. doi: 10.1128/aac.40.12.2884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Doern G. V., Brueggemann A. B., Pierce G., Holley H. P., Jr, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother. 1997 Feb;41(2):292–297. doi: 10.1128/aac.41.2.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Doern G. V., Brueggemann A., Holley H. P., Jr, Rauch A. M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996 May;40(5):1208–1213. doi: 10.1128/aac.40.5.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Eliopoulos G. M., Klimm K., Eliopoulos C. T., Ferraro M. J., Moellering R. C., Jr In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrob Agents Chemother. 1993 Feb;37(2):366–370. doi: 10.1128/aac.37.2.366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gould I. M., Forbes K. J., Gordon G. S. Quinolone resistant Haemophilus influenzae. J Antimicrob Chemother. 1994 Jan;33(1):187–188. doi: 10.1093/jac/33.1.187. [DOI] [PubMed] [Google Scholar]
  10. Hooper D. C., Wolfson J. S. Fluoroquinolone antimicrobial agents. N Engl J Med. 1991 Feb 7;324(6):384–394. doi: 10.1056/NEJM199102073240606. [DOI] [PubMed] [Google Scholar]
  11. Jorgensen J. H., Redding J. S., Maher L. A., Howell A. W. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol. 1987 Nov;25(11):2105–2113. doi: 10.1128/jcm.25.11.2105-2113.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lee B. L., Padula A. M., Kimbrough R. C., Jones S. R., Chaisson R. E., Mills J., Sande M. A. Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med. 1991 Aug 15;325(7):520–521. doi: 10.1056/nejm199108153250719. [DOI] [PubMed] [Google Scholar]
  13. Pan X. S., Ambler J., Mehtar S., Fisher L. M. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996 Oct;40(10):2321–2326. doi: 10.1128/aac.40.10.2321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Piddock L. J., Jin Y. F. Selection of quinolone-resistant mutants of Haemophilus influenzae and Streptococcus pneumoniae. J Antimicrob Chemother. 1992 Jul;30(1):109–110. doi: 10.1093/jac/30.1.109. [DOI] [PubMed] [Google Scholar]
  15. Piddock L. J. New quinolones and gram-positive bacteria. Antimicrob Agents Chemother. 1994 Feb;38(2):163–169. doi: 10.1128/aac.38.2.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pérez-Trallero E., Garcia-Arenzana J. M., Jimenez J. A., Peris A. Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1990 Dec;9(12):905–906. doi: 10.1007/BF01967510. [DOI] [PubMed] [Google Scholar]
  17. Wolfson J. S., Hooper D. C. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989 Oct;2(4):378–424. doi: 10.1128/cmr.2.4.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Woodcock J. M., Andrews J. M., Boswell F. J., Brenwald N. P., Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother. 1997 Jan;41(1):101–106. doi: 10.1128/aac.41.1.101. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES